Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - paklitakselis - koncentratas infuziniam tirpalui - 6 mg/ml - paclitaxel

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

gedeon richter plc - fentanilis - transderminis pleistras - 50 µg/val; 75 µg/val; 100 µg/val.; 25 µg/val - fentanyl

Union européenne - lituanien - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - daugybinė mieloma - antinavikiniai vaistai - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - kabazitakselis - koncentratas infuziniam tirpalui - 10 mg/ml - cabazitaxel

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - norepinefrinas - koncentratas infuziniam tirpalui - 1 mg/ml - norepinephrine

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - kabazitakselis - koncentratas infuziniam tirpalui - 10 mg/ml - cabazitaxel

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - norepinefrinas - koncentratas infuziniam tirpalui - 1 mg/ml - norepinephrine

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - norepinefrinas - koncentratas infuziniam tirpalui - 1 mg/ml - norepinephrine

Union européenne - lituanien - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - kiti nervų sistemos vaistai - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Union européenne - lituanien - EMA (European Medicines Agency)

accord healthcare s.l.u. - kabazitakselis - prostatos navikai, kastracija-atsparus - antinavikiniai vaistai - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.